|
|
 |
|
Viewing report
|
|
|
|
European Orphan Diseases Market
Frost & Sullivan, Dec 2008, Pages: 88
This research service deals with market drivers, restraints, market trends, competitive structure , revenues, technology trends and market attractiveness analysis of the European orphan diseases market.
Research Overview
This Frost & Sullivan research service titled European Orphan Diseases Market provides insight into industry challenges, market drivers and market restraints and includes strategic recommendations. Revenue forecasts are offered along with an in-depth examination of the market’s competitive structure and a brand analysis of current market offerings. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: orphan diseases, Gaucher’s Disease and Pulmonary Arterial Hypertension (PAH) markets in Europe.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.
Market Overview
Niche Blockbusters Offer Promising Growth Potential
The patent expiry of blockbuster molecules has resulted in large pharmaceutical companies confronting intense competition from generics. CEOs have had to rethink strategies and devise alternative approaches to maintain the growth of their organisation and satisfy stakeholders. A focus on the market for niche blockbuster drugs represents a potential strategy that can be pursued by large pharmaceutical companies. For instance, there has been strong growth in the orphan diseases market, due to various incentives and benefits provided by governments. In the European Union (EU), the emphasis is on orphan diseases, as it is a promising, emergent market that offers the prospect of assured return on investment (ROI).
As leading pharmaceutical companies are facing increasing competition because of impending patent expiries of blockbuster drugs, a number of companies are pursuing merger and acquisition of small biotechnology companies. 'The market is set to witness major consolidation due to mergers and acquisitions among big pharmaceuticals and small biotech companies,' notes the analyst of this research. 'The lack of adequate investment to support the development of newer therapies and technologies has been a major challenge for small biotechnology companies, resulting in their tilt towards merging with larger companies.'
The European orphan diseases market grapples with numerous challenges. Of these, the most serious are the lack of awareness, poor diagnosis and limited accessibility of orphan drugs. 'There are diverse policies among EU member countries with regard to the accessibility of orphan drugs,' remarks the analyst. 'This is retarding market expansion.'
EU-wide harmonisation in the context of accessibility processes and price policies will reduce delays in the availability of orphan drugs. EU-wide co-ordination will also help in streamlining the regulatory process governing these drugs. EU healthcare ministers should encourage frequent discussions with patients, patient support groups and industry representatives to ensure a transparent and rapid approval process for orphan drugs.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following markets in this research:
- Orphan diseases
- Gaucher’s disease
- Pulmonary arterial hypertension
- Frost & Sullivan Growth Partnership Services
Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues
Orphan Drug Strategies
Orphan Drugs Pipeline Analysis: Wider Incentives Encourage Orphan Drug R&D
The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2006)
Commercial Strategies in Cardiovascular and Metabolic Diseases: Successful Market Positioning at Company and Brand Level becomes Paramount
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
Italy Pharmaceuticals and Healthcare Report Q2 2009
Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world�s second largest market
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan
State of the Clinical Trials Industry, 2009
Stem Cell Research in Cardiology
Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
|
|
|
